Will the Phase 3 trial "Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis." reach primary completion on or before Jul 24, 2029?

Resolves Yes if ClinicalTrials.gov record NCT06846281 (Novartis Pharmaceuticals) shows an actual primary completion date on or before Jul 24, 2029. Registered date at generation: Jul 24, 2029.

Outcome verified from clinicaltrials.gov.

1. Market open

   Jul 17, 2026, 7:40 AM UTC
2. Market closes

   By Jul 24, 2029, 11:59 PM UTC
3. Projected payout

   Shortly after the market closes

Trading on material non-public information is prohibited. Markets are for entertainment and informational purposes using free Pulse Credits — no real-money wagering. If you believe a participant has acted on inside information, please report it.